Prostate cancer in African-American men is associated with specific 
changes in the IL-16 gene, according to researchers at the University of
 Illinois at Chicago College of Medicine.
The study, published online in the journal Cancer Epidemiology, Biomarkers & Prevention, establishes the association of IL-16 with prostate cancer in men of both African and European descent.
"This provides us with a new potential biomarker for prostate 
cancer," says principal investigator Rick Kittles, UIC associate 
professor of medicine in hematology/oncology.
Previously identified changes in the gene for IL-16, an immune system
 protein, were associated with prostate cancer in men of European 
descent. But the same changes in the gene's coded sequence -- called 
"polymorphisms" -- did not confer the same risk in African Americans.
Doubt was cast on IL-16's role in prostate cancer when researchers 
were unable to confirm that the IL-16 polymorphisms identified in whites
 were also important risk factors in African Americans, Kittles said.
Kittles and his colleagues used a technique called imputation -- a 
type of statistical extrapolation -- that allowed them to see new 
patterns of association and identify new places in the gene to look for 
polymorphisms. They found changes elsewhere in the IL-16 gene that were 
associated with prostate cancer and that were unique to African 
Americans.
Polymorphisms result from DNA mutations and emerge in the ancestral 
history of different populations. People of African descent are much 
more genetically diverse than whites, Kittles said, making the search 
for polymorphisms associated with disease more difficult.
Although the effect of the particular changes to the gene appear to 
be different in men of African versus European descent, it is likely 
that several of the polymorphisms in the gene alter the function of the 
IL-16 protein.
"This confirms the importance of IL-16 in prostate cancer and leads 
us in a new direction," Kittles said. "Very little research has been 
done on IL-16, so not much is known about it."
"We now need to explore the functional role of IL-16 to understand the role it is playing in prostate cancer," he said.
Ken Batai, graduate student in the UIC Institute for Human Genetics, 
was first author of the study. Other authors were Ebony Shah, Jennifer 
Newsome, and Maria Ruden of the UIC Institute for Human Genetics; Adam 
Murphy of Northwestern University; and Chiledum Ahaghotu of Howard 
University Hospital in Washington, D.C.
The study was supported by grants from the Department of Defense 
(DAMD W81XWH-07-1-0203) and National Cancer Institute/National 
Institutes of Health (RC2-CA148085-01 and U01-CA136792-02S1.)
Journal Reference:
- Ken Batai, Ebony Shah, Adam B. Murphy, Jennifer Newsome, Maria Ruden, Chiledum Ahaghotu, and Rick A. Kittles. Fine-mapping of IL-16 gene and prostate cancer risk in African Americans. Cancer Epidemiology, Biomarkers & Prevention, 2012; DOI: 10.1158/1055-9965.EPI-12-0707
 
Courtesy: ScienceDaily 

No comments:
Post a Comment